In contrast, PD-L1 inhibitors such as Atezolizumab selectively bind to their ligand, which is expressed in tumor cells, stromal cells and antigen-presenting cells in the tumor microenvironment, allowing the interaction between PD-1 and PD-L2 to be preserved. Here, PDCD1LG2 is linked to neoplasm.